Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22775073 | 0.89 | CFTR (0.64) | CFTR | |
| SCHEMBL29028904 | 0.83 | CFTR (0.51) | CFTR | |
| SCHEMBL29381231 | 0.83 | CFTR (0.51) | CFTR | |
| SCHEMBL14783594 | 0.83 | CFTR (0.76) | CFTR | |
| SCHEMBL2373012 | 0.81 | CFTR (0.70) | CFTR | |
| SCHEMBL29699252 | 0.81 | CFTR (0.70) | CFTR | |
| SCHEMBL11928252 | 0.81 | CFTR (0.57) | CFTR | |
| SCHEMBL14783265 | 0.80 | CFTR (0.46) | CFTR | |
| SCHEMBL2372587 | 0.80 | CFTR (0.71) | CFTR | |
| SCHEMBL23616410 | 0.78 | CFTR (0.61) | CFTRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| CN-103930109-B | The substituted heterocyclyl amides of N- | NOVARTIS AG (CH) | 2016-11-30 | — | — | CN | claimed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | claimed |
| US-9056867-B2 | N-substituted heterocyclyl carboxamides | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | claimed |
| CN-102892758-B | Pyridine and pyrazine derivatives for the treatment of CF | NOVARTIS AG | 2015-01-07 | — | — | CN | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | CFTR 1/4885KDM4E 3848/4885ALDH1A1 1015/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CFTR 1/4885KDM4E 1779/4885ALDH1A1 2710/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | CFTR 146/4885KDM4E 3399/4885ALDH1A1 2147/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | CFTR 1/4885KDM4E 1465/4885ALDH1A1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.